Provided by Tiger Fintech (Singapore) Pte. Ltd.

AIM ImmunoTech Inc.

2.57
-0.0400-1.53%
Post-market: 2.620.0492+1.91%19:01 EDT
Volume:24.93K
Turnover:64.32K
Market Cap:6.96M
PE:-0.11
High:2.66
Open:2.63
Low:2.55
Close:2.61
52wk High:20.35
52wk Low:2.33
Shares:2.71M
Float Shares:2.65M
Volume Ratio:0.35
T/O Rate:0.94%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-24.1217
EPS(LYR):-30.9192
ROE:-3138.91%
ROA:-104.62%
PB:-1.06
PE(LYR):-0.08

Loading ...

Industry's First Enterprise AI Adoption Maturity Model (AIM²) Unveiled at Bund Conference

Deep News
·
Sep 12

RentGuarantor Holdings PLC Reports Strong Growth and Strategic AIM Market Move

TIPRANKS
·
Sep 11

AIM ImmunoTech Inc. Showcases Promising Ampligen Data for Pancreatic Cancer at Marie Sklodowska-Curie Symposium in Poland

Reuters
·
Sep 04

Anexo Group to Delist From London's AIM as It Goes Private

Dow Jones
·
Aug 27

Press Release: AIM ImmunoTech Announces Release of the Next CEO Corner Segment

Dow Jones
·
Aug 21

Vulcan Two Group Seeks AIM Stock Market IPO

Dow Jones
·
Aug 19

AIM ImmunoTech Reports Q2 2025 Results: Net Loss Increases to $2.8M, EPS Drops to $(3.68)

Reuters
·
Aug 15

AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire
·
Aug 15

AIM ImmunoTech Inc. to Present at Webull Financial Corporate Connect Webinar Series

Reuters
·
Aug 14

AIM ImmunoTech Unveils Promising Clinical Data on Ampligen's Impact in Late-Stage Pancreatic Cancer and Endometriosis at International Symposium

Reuters
·
Aug 06

BRIEF-Aim Immunotech Inc - Ampligen With Imfinzi Shows Positive Results In Pancreatic Cancer

Reuters
·
Aug 04

AIM ImmunoTech Inc - Ampligen With Imfinzi Shows Positive Results in Pancreatic Cancer

THOMSON REUTERS
·
Aug 04

AIM ImmunoTech Inc. Secures U.S. Patent for Ampligen® in Combination with PD-L1 Drugs for Cancer Treatment

Reuters
·
Aug 04

AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen® Clinical Development Toward Pancreatic Cancer Approval

GlobeNewswire
·
Aug 04

AIM ImmunoTech Announces Closing of $8.0 Million Public Offering

GlobeNewswire
·
Jul 31

US Stocks Mixed; Procter & Gamble Posts Upbeat Earnings

Benzinga
·
Jul 29

AIM ImmunoTech Inc. Announces $8 Million Public Offering with Maxim Group as Sole Placement Agent

Reuters
·
Jul 29

Amex Halt Add Info Lst 14.160000

THOMSON REUTERS
·
Jul 28

US Stocks Mixed; Enterprise Products Partners Posts Upbeat Earnings

Benzinga
·
Jul 28

Amex Halt Add Info Lst 14.850000

THOMSON REUTERS
·
Jul 28